In B16F10 melanoma tumor-bearing mice, pIL-12 EP1 and pIL-12 EP2 treatment partially controlled disease progression and around 65–80% of mice achieved long-term disease-free survival (Figure 1C). This evidence concerns the gene SPRR2A and neoplasm.